Deep Dive: DMT The Human Side Ep04
# The Human Side of DMT: Trust, Fragility, and Why "Prove It" Kills Progress
Dr. Laposata on the interpersonal realities behind diagnostic management teams — why trust matters, why clinicians engage, and what holds DMTs back from wider adoption.
## Summary
Dr. Laposata shifts
The Human Side of DMT: Trust, Fragility, and Why "Prove It" Kills Progress
Dr. Laposata on the interpersonal realities behind diagnostic management teams — why trust matters, why clinicians engage, and what holds DMTs back from wider adoption.
Episode Summary
Dr. Laposata shifts the conversation from DMT mechanics to the human dynamics that determine whether a DMT succeeds or collapses. He draws on decades of experience — from launching coagulation rounds at MGH in the mid-1990s to leading multiple DMTs at Vanderbilt — to explain why trust is built through results, not promises, and why the "prove it to me" mentality has been the single biggest barrier to adoption.
Key Takeaways
- Trust in DMT is earned incrementally: Clinicians commit to a pathologist's recommendations only after repeated, useful interactions. At MGH, vascular surgeons trusted coagulation advice so completely that a sign at the nurses station read, "Only Pathologists are allowed to consult on coagulation cases."
- Clinicians engage when they see results, not proposals: Dr. Laposata started coagulation rounds at MGH by simply announcing they were happening. Within two weeks, the volume demanded five days a week; caseload grew from 5 per day to 35, and a colleague eventually reached 80 per day.
- DMT is incredibly fragile: One negative experience or perceived error can destroy clinician confidence. A commercial lab representative walked out of a meeting after 20 minutes because their focus was purely financial, and a primary care physician confided that his first thought every time a patient walks in is, "Will they sue me?"
- Administrative support is decisive: At Vanderbilt, the chief medical officer's endorsement of coagulation rounds gave the green light to expand into infectious disease and microbiology DMTs — clearly overruling a division head who vocally opposed the effort.
- Pathologists must bring urgency to DMT work: Too many in pathology treat DMT interpretation as optional or deferrable. Dr. Laposata argues that if surgical pathologists can't let a case sit for two days, clinical pathologists shouldn't either.
- Financial benefits are real but hard to quantify: At Vanderbilt, coagulation rounds reduced pulmonary embolism (PE) length of stay from four days to two, saving roughly $2,000 per patient per day — but the savings were invisible to the CFO because they showed up in another department's budget.
- Don't wait for outcome studies to start a DMT: Dr. Laposata calls the demand for randomized controlled trial evidence before launching a DMT "useless." Knowing the right diagnosis for the next patient is its own justification.
Chapters
- Trust as the Foundation of DMT
- How Clinicians Actually Engage
- The Fragility of DMT Relationships
- Administrative Support Makes or Breaks DMT Expansion
- Common Pitfalls for Pathologists Entering DMT
- The Cost of Waiting for Proof
Notable Quotes
"Only Pathologists are allowed to consult on coagulation cases."
"Every time somebody comes through my door that I see for the first time my first question to myself is will they sue me."
"Prove it to me before you ever get started is really what has held the DMT back."
